Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Oct;92(10):2243-2247.
doi: 10.1002/jmv.26145. Epub 2020 Jun 19.

Clinical performance of different SARS-CoV-2 IgG antibody tests

Niko Kohmer  1 , Sandra Westhaus  1 , Cornelia Rühl  1 , Sandra Ciesek  1   2 , Holger F Rabenau  1
Affiliations
Comparative Study

Clinical performance of different SARS-CoV-2 IgG antibody tests

Niko Kohmer et al. J Med Virol. 2020 Oct.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological assays are urgently needed for rapid diagnosis, contact tracing, and for epidemiological studies. So far, there is limited data on how commercially available tests perform with real patient samples, and if positive tested samples show neutralizing abilities. Focusing on IgG antibodies, we demonstrate the performance of two enzyme-linked immunosorbent assay (ELISA) assays (Euroimmun SARS-CoV-2 IgG and Vircell COVID-19 ELISA IgG) in comparison to one lateral flow assay (FaStep COVID-19 IgG/IgM Rapid Test Device) and two in-house developed assays (immunofluorescence assay [IFA] and plaque reduction neutralization test [PRNT]). We tested follow up serum/plasma samples of individuals polymerase chain reaction-diagnosed with COVID-19. Most of the SARS-CoV-2 samples were from individuals with moderate to the severe clinical course, who required an in-patient hospital stay. For all examined assays, the sensitivity ranged from 58.8 to 76.5% for the early phase of infection (days 5-9) and from 93.8% to 100% for the later period (days 10-18).

Keywords: ELISA; IFA; IgG; PRNT; SARS-CoV-2; antibody tests.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Results of the for sensitivity tested samples in the ELISA assays and PRNT; A, Euroimmun ELISA ratios of tested samples; B, Vircell ELISA Indexes for tested samples; C, PRNT Titer for tested samples. *Days 5 to 9 /**Days 10 to 18 after confirmed SARS‐CoV‐2 PCR. ELISA, enzyme‐linked immunosorbent assay; PRNT, plaque reduction neutralization test
See this image and copyright information in PMC

References

    1. Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al‐Nasser AD. SARS‐CoV‐2 and coronavirus disease 2019: what we know so far. Pathogens. 2020;9(3):231. - PMC - PubMed
    1. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID‐19: systematic review. J Med Virol. 2020.1–9. 10.1002/jmv.25961 - DOI - PMC - PubMed
    1. Ou X, Liu Y, Lei X, et al.Characterization of spike glycoprotein of SARS‐CoV‐2 on virus entry and its immune cross‐reactivity with SARS‐CoV. Nat Commun. 2020;11:1620. - PMC - PubMed
    1. Liu W, Liu L, Kou G, et al. Evaluation of nucleocapsid and spike protein‐based ELISAs for detecting antibodies against SARS‐CoV‐2. J Clin Microbiol. 2020;58(6):e00461. - PMC - PubMed
    1. Cassaniti I, Novazzi F, Giardina F, et al. Performance of VivaDiag COVID‐19 IgM/IgG rapid test is inadequate for diagnosis of COVID‐19 in acute patients referring to emergency room department. J Med Virol. 2020. - PMC - PubMed

Publication types

MeSH terms